Terms: = Pancreatic cancer AND RB1, OSRC, ENSG00000139687, 5925, RB, P06400 AND Treatment
87 results:
1. CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma.
Cheng K; Zhou Z; Chen Q; Chen Z; Cai Y; Cai H; Wu S; Gao P; Cai Y; Zhou J; Wang X; Wu Z; Peng B
Sci Rep; 2024 Apr; 14(1):8389. PubMed ID: 38600093
[TBL] [Abstract] [Full Text] [Related]
2. NET G3 vs NEC: p53 and rb1 Immunolabeling in High-grade Gastrointestinal Neuroendocrine Neoplasms - Is It Enough for the Differential Diagnosis?
Dinu A; Aschie M; Cozaru GC; Mitroi AF; Grasa CN; Iordache IE; Deacu M; Orasanu CI; Nicolau AA; Baltatescu GI
J Gastrointestin Liver Dis; 2023 Jun; 32(2):162-169. PubMed ID: 37345605
[TBL] [Abstract] [Full Text] [Related]
3. Molecular and Functional Heterogeneity of Primary pancreatic Neuroendocrine Tumors and Metastases.
Guo Y; Tian C; Cheng Z; Chen R; Li Y; Su F; Shi Y; Tan H
Neuroendocrinology; 2023; 113(9):943-956. PubMed ID: 37232011
[TBL] [Abstract] [Full Text] [Related]
4. Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data.
Boilève A; Faron M; Fodil-Cherif S; Bayle A; Lamartina L; Planchard D; Tselikas L; Kanaan C; Scoazec JY; Ducreux M; Italiano A; Baudin E; Hadoux J
Eur J Cancer; 2023 Jun; 186():122-132. PubMed ID: 37062210
[TBL] [Abstract] [Full Text] [Related]
5. Design, synthesis and biological evaluation of 2-((4-sulfamoylphenyl)amino)-pyrrolo[2,3-d]pyrimidine derivatives as CDK inhibitors.
Yang B; Quan Y; Zhao W; Ji Y; Yang X; Li J; Li Y; Liu X; Wang Y; Li Y
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2169282. PubMed ID: 36656085
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic Factors across Poorly Differentiated Neuroendocrine Neoplasms: A Pooled Analysis.
Centonze G; Maisonneuve P; Prinzi N; Pusceddu S; Albarello L; Pisa E; Barberis M; Vanoli A; Spaggiari P; Bossi P; Cattaneo L; Sabella G; Solcia E; La Rosa S; Grillo F; Tagliabue G; Scarpa A; Papotti M; Volante M; Mangogna A; Del Gobbo A; Ferrero S; Rolli L; Roca E; Bercich L; Benvenuti M; Messerini L; Inzani F; Pruneri G; Busico A; Perrone F; Tamborini E; Pellegrinelli A; Kankava K; Berruti A; Pastorino U; Fazio N; Sessa F; Capella C; Rindi G; Milione M
Neuroendocrinology; 2023; 113(4):457-469. PubMed ID: 36417840
[TBL] [Abstract] [Full Text] [Related]
7. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant pancreatic cancer.
Goodwin CM; Waters AM; Klomp JE; Javaid S; Bryant KL; Stalnecker CA; Drizyte-Miller K; Papke B; Yang R; Amparo AM; Ozkan-Dagliyan I; Baldelli E; Calvert V; Pierobon M; Sorrentino JA; Beelen AP; Bublitz N; Lüthen M; Wood KC; Petricoin EF; Sers C; McRee AJ; Cox AD; Der CJ
Cancer Res; 2023 Jan; 83(1):141-157. PubMed ID: 36346366
[TBL] [Abstract] [Full Text] [Related]
8. Discovery of a novel NUAK1 inhibitor against pancreatic cancer.
Seo MS; Jung KH; Kim K; Lee JE; Han BS; Ko S; Kim JH; Hong S; Lee SH; Hong SS
Biomed Pharmacother; 2022 Aug; 152():113241. PubMed ID: 35691157
[TBL] [Abstract] [Full Text] [Related]
9. Consensus Statement on Mandatory Measurements for pancreatic cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement.
Pijnappel EN; Suurmeijer JA; Koerkamp BG; Kos M; Siveke JT; Salvia R; Ghaneh P; van Eijck CHJ; van Etten-Jamaludin FS; Abrams R; Brasiuniene B; Büchler MW; Casadei R; van Laethem JL; Berlin J; Boku N; Conroy T; Golcher H; Sinn M; Neoptolemos JP; van Tienhoven G; Besselink MG; Wilmink JW; van Laarhoven HWM
JAMA Oncol; 2022 Jun; 8(6):929-937. PubMed ID: 35446336
[TBL] [Abstract] [Full Text] [Related]
10. Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors.
Garcia-Carbonero R; Bazan-Peregrino M; Gil-Martín M; Álvarez R; Macarulla T; Riesco-Martinez MC; Verdaguer H; Guillén-Ponce C; Farrera-Sal M; Moreno R; Mato-Berciano A; Maliandi MV; Torres-Manjon S; Costa M; Del Pozo N; Martínez de Villarreal J; Real FX; Vidal N; Capella G; Alemany R; Blasi E; Blasco C; Cascalló M; Salazar R
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338084
[TBL] [Abstract] [Full Text] [Related]
11. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects.
Bazan-Peregrino M; Garcia-Carbonero R; Laquente B; Álvarez R; Mato-Berciano A; Gimenez-Alejandre M; Morgado S; Rodríguez-García A; Maliandi MV; Riesco MC; Moreno R; Ginestà MM; Perez-Carreras M; Gornals JB; Prados S; Perea S; Capella G; Alemany R; Salazar R; Blasi E; Blasco C; Cascallo M; Hidalgo M
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 35149591
[TBL] [Abstract] [Full Text] [Related]
12. Determining oncogenic patterns and cancer predisposition through the transcriptomic profile in Mitchell-Riley syndrome with heterotopic gastric mucosa and duodenal atresia: a case report.
Calcaterra V; Chiricosta L; Mazzon E; Gugnandolo A; Alberti D; Maestri L; Meroni M; Vestri E; Verduci E; Dilillo D; Zuccotti G; Pelizzo G
Orphanet J Rare Dis; 2021 Oct; 16(1):455. PubMed ID: 34715892
[TBL] [Abstract] [Full Text] [Related]
13. Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs.
Shi M; Fan Z; Xu J; Yang J; Li Y; Gao C; Su P; Wang X; Zhan H
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188637. PubMed ID: 34678439
[TBL] [Abstract] [Full Text] [Related]
14. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.
Venizelos A; Elvebakken H; Perren A; Nikolaienko O; Deng W; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Krogh M; Sorbye H; Knappskog S
Endocr Relat Cancer; 2021 Nov; 29(1):1-14. PubMed ID: 34647903
[TBL] [Abstract] [Full Text] [Related]
15. Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer.
Dang F; Nie L; Zhou J; Shimizu K; Chu C; Wu Z; Fassl A; Ke S; Wang Y; Zhang J; Zhang T; Tu Z; Inuzuka H; Sicinski P; Bass AJ; Wei W
Nat Commun; 2021 Sep; 12(1):5386. PubMed ID: 34508104
[TBL] [Abstract] [Full Text] [Related]
16. Kinesin 12 (KIF15) contributes to the development and tumorigenicity of prostate cancer.
Qureshi Z; Ahmad M; Yang WX; Tan FQ
Biochem Biophys Res Commun; 2021 Oct; 576():7-14. PubMed ID: 34474246
[TBL] [Abstract] [Full Text] [Related]
17. The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets.
van Riet J; van de Werken HJG; Cuppen E; Eskens FALM; Tesselaar M; van Veenendaal LM; Klümpen HJ; Dercksen MW; Valk GD; Lolkema MP; Sleijfer S; Mostert B
Nat Commun; 2021 Jul; 12(1):4612. PubMed ID: 34326338
[TBL] [Abstract] [Full Text] [Related]
18. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in pancreatic Ductal Adenocarcinoma.
Willobee BA; Gaidarski AA; Dosch AR; Castellanos JA; Dai X; Mehra S; Messaggio F; Srinivasan S; VanSaun MN; Nagathihalli NS; Merchant NB
Mol Cancer Ther; 2021 Jul; 20(7):1246-1256. PubMed ID: 34001634
[TBL] [Abstract] [Full Text] [Related]
19. Exploiting a Rose Bengal-bearing, oxygen-producing nanoparticle for SDT and associated immune-mediated therapeutic effects in the treatment of pancreatic cancer.
Nicholas D; Nesbitt H; Farrell S; Logan K; McMullin E; Gillan T; Kelly P; O'Rourke D; Porter S; Thomas K; O'Hagan BMG; Nomikou N; Callan B; Callan JF; McHale AP
Eur J Pharm Biopharm; 2021 Jun; 163():49-59. PubMed ID: 33798727
[TBL] [Abstract] [Full Text] [Related]
20. Platinum-Based treatment for Well- and Poorly Differentiated pancreatic Neuroendocrine Neoplasms.
Pulvirenti A; Raj N; Cingarlini S; Pea A; Tang LH; Luchini C; Chou JF; Grego E; Marinova I; Capanu M; Landoni L; Scarpa A; Allen PJ; Klimstra DS; Reidy-Lagunes DL
Pancreas; 2021 Feb; 50(2):138-146. PubMed ID: 33565789
[TBL] [Abstract] [Full Text] [Related]
[Next]
